<DOC>
	<DOCNO>NCT01230437</DOCNO>
	<brief_summary>The airway lung line specialised cell call airway epithelial cell . As well interface lung air breathe ; airway epithelial cell ( AEC ) function alter people respiratory disease asthma . AEC secrete many mediator contribute asthma symptom also contribute asthmatic inflammation lung . The study cell difficult location deep lung . Nasal airway epithelial cell provide useful easily accessible model model low airway cell . This study examine whether asthma medication Singulair ( montelukast ) inhibit inflammatory secretion nasal AEC asthmatic patent also allergic rhinitis compare patient asthma alone . We also examine montelukast differential modulate effect two patient group .</brief_summary>
	<brief_title>Montelukast Nasal Epithelial Cell Inflammatory Responses Asthma Rhinitis</brief_title>
	<detailed_description>Hypothesis The inflammatory secretory profile nasal airway epithelial cell ( NEC ) culture asthmatic concomitant allergic rhinitis ( AR ) differ NEC patient asthma alone . Treatment ( vitro vivo ) montelukast may differential modulate effect two patient group . For primary objective proposal use nasal AEC asthmatic without concomitant AR ascertain difference pro-inflammatory cytokine chemokine production two group determine whether vitro treatment montelukast differential modulate effect NEC secretion . In secondary pilot study modulate effect montelukast AEC secretion vitro correlate vivo response montelukast withdrawal . This sub study provide pilot data indicate whether vivo response montelukast predict vitro effect NEC .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>stable physician confirm mild/moderate asthma ( Steps 14 BTS/SIGN guideline &lt; 10 packyear smoke history Currently take montelukast document clinical history benefit Nasal corticosteroid therapy</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>montelukast</keyword>
	<keyword>asthma</keyword>
	<keyword>allergic rhinitis</keyword>
	<keyword>nasal epithelial cell</keyword>
	<keyword>inflammatory mediator</keyword>
</DOC>